Skip to main content
. Author manuscript; available in PMC: 2014 Jul 1.
Published in final edited form as: Neuropharmacology. 2013 Jan 23;70:112–121. doi: 10.1016/j.neuropharm.2013.01.007

Fig. 2.

Fig. 2

The effects of commercially available 5-HT2C agonists (A), 4-phenyl-2-aminotetralin 5-HT2C agonists (B), and selective 5-HT2 antagonists (C) on locomotion following administration of saline, DOI (1 mg/kg), or DOI in combination with the various compounds. The dose (mg/kg) is indicated in parentheses. “2nd” refers to test sessions in which the antagonist was administered after DOI. *Indicates a statistically significant difference from DOI alone. +Indicates a statistically significant difference from vehicle alone.